Zina Affas Besse
Directeur/Membre du Conseil chez Alydia Health, Inc.
Profil
Zina Affas Besse has held various director positions in companies such as Eyenuk, Inc., Alydia Health, Inc., and LimmaTech Biologics AG.
She is also an advisor at LHGP Asset Management LLP (Private Equity).
Postes actifs de Zina Affas Besse
| Sociétés | Poste | Début |
|---|---|---|
Alydia Health, Inc.
 Alydia Health, Inc. Medical SpecialtiesHealth Technology Alydia Health, Inc. operates as medical device company which provides solution to postpartum hemorrhage. The company was founded by Nathan Bair and Jessie Becke on May 8, 2018 and is headquartered in Menlo Park, CA. | Directeur/Membre du Conseil | - |
Eyenuk, Inc.
 Eyenuk, Inc. Medical SpecialtiesHealth Technology Eyenuk, Inc. provides health care services. The firm focuses on identifying patients suffering from potentially blinding eye diseases and preserving their vision. It is developing a portfolio of products based on its proprietary retinal image analysis technology. Its products include EyeArt, EyeMark, EyeApp, and EyeSeeAMD. The company was founded by Kaushal Solanki in 2010 and is headquartered in Woodland Hills, CA. | Directeur/Membre du Conseil | 17/10/2022 |
LHGP Asset Management LLP (Private Equity)
 LHGP Asset Management LLP (Private Equity) Investment ManagersFinance LHGP Asset Management LLP (Private Equity) (LHGP Asset Management) is a private equity arm of Lion's Head Global Partners LLP founded in 2018. The firm is headquartered in Westminster, United Kingdom. | Consultant / Advisor | - |
LimmaTech Biologics AG
 LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Directeur/Membre du Conseil | 09/10/2023 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
LHGP Asset Management LLP (Private Equity)
LHGP Asset Management LLP (Private Equity) Investment ManagersFinance LHGP Asset Management LLP (Private Equity) (LHGP Asset Management) is a private equity arm of Lion's Head Global Partners LLP founded in 2018. The firm is headquartered in Westminster, United Kingdom. | Finance |
Eyenuk, Inc.
Eyenuk, Inc. Medical SpecialtiesHealth Technology Eyenuk, Inc. provides health care services. The firm focuses on identifying patients suffering from potentially blinding eye diseases and preserving their vision. It is developing a portfolio of products based on its proprietary retinal image analysis technology. Its products include EyeArt, EyeMark, EyeApp, and EyeSeeAMD. The company was founded by Kaushal Solanki in 2010 and is headquartered in Woodland Hills, CA. | Health Technology |
Alydia Health, Inc.
Alydia Health, Inc. Medical SpecialtiesHealth Technology Alydia Health, Inc. operates as medical device company which provides solution to postpartum hemorrhage. The company was founded by Nathan Bair and Jessie Becke on May 8, 2018 and is headquartered in Menlo Park, CA. | Health Technology |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Commercial Services |
